Open AccessDevelopment of advanced conduction disturbances following balloon‐expandable transcatheter aortic valve replacement leads to poorer clinical outcomes
Author(s) -
Ashraf Hasan,
Fortuin Floyd D.,
Sweeney John,
DeValeria Patrick A.,
Lanza Louis A.,
Ramsay Gary,
Maranzano Pedro,
Patrick Lorna,
Scott Luis R.
Publication year - 2020
Publication title -
journal of arrhythmia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 21
eISSN - 1883-2148
pISSN - 1880-4276
DOI - 10.1002/joa3.12383
Subject(s) - medicine , cardiology , valve replacement , left bundle branch block , ejection fraction , stenosis , aortic valve stenosis , retrospective cohort study , bundle branch block , heart failure , electrocardiography
Background Transcatheter aortic valve replacement (TAVR) is a reliable method of treating patients with severe aortic stenosis, but is associated with postprocedure conduction defects. Objective The purpose of this study was to compare clinical outcomes in patients who developed advanced conduction defects post‐TAVR to those who did not. Methods We conducted a retrospective chart review of 243 patients who underwent balloon‐expandable TAVR with the Edwards Sapien valve to determine the incidence of advanced conduction defects in our cohort. We compared clinical outcomes including overall mortality, improvement in symptomatology, and improvement in left ventricular ejection fraction. Results Among the 243 patients included in the study, 9.1% (22/243) required permanent pacemaker (PPM); 19.8% (48/243) developed left bundle branch block (LBBB), and 71.2% (173/243) did not develop any permanent advanced conduction defects. Overall 1‐year mortality was similar across all three groups. There was significant improvement in New York Heart Association functional capacity of all groups post‐TAVR, but this was much less in the PPM group (45.5% vs 68.8%, P = .04). Postprocedure from TAVR, patients with LBBB or PM were less likely to have improvement in their ejection fraction (net loss of −0.7% for LBBB and −5.7% for PPM compared to a net gain of 2.3% for no‐LBBB/PM ( P = .02). Conclusion Patients who develop LBBB or require PM post‐TAVR with Edwards Sapien valves are less likely to improve New York Heart Association functional capacity and more likely to have no improvement or deterioration of their pre‐TAVR left ventricular ejection fraction.